Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zetia in Non-alcoholic Steatohepatitis
NCT01766713Phase 2Completed
- Sponsor
- University of California, San Diego
- Start
- Jan 2013
- Primary completion
- Aug 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ezetimibe in Nonalcoholic steatohepatitis (NASH), sponsored by University of California, San Diego. Primary endpoint: Change in Liver Fat as Measured by MRI-PDFF at 24 weeks. Started Jan 2013; status: completed.
02
Drugs
ezetimibe
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT01766713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01766713.